Basic Information
| LncRNA/CircRNA Name | MAFG-AS1 |
| Synonyms | NA |
| Region | GRCh38_17:81927829-81930753 |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | RT-qPCR |
| Sample | gastric cancer tissues,cell lines |
| Expression Pattern | up-regulated |
| Function Description | gastric cancer tissues and cell lines had remarkably increased MAFG-AS1 expression in comparison to normal gastric mucosa tissues and normal human gastric epithelial cell line, and high MAFG-AS1 expression was positively associated with diffuse type, advanced clinical stage, extensive depth of invasion, more lymph node metastasis, and present distant metastasis in gastric cancer patients.knocking down MAFG-AS1 expression inhibited gastric cancer cell proliferation, migration and invasion in vitro. |
| Pubmed ID | 32079456 |
| Year | 2020 |
| Title | MAFG-AS1 is a novel clinical biomarker for clinical progression and unfavorable prognosis in gastric cancer |
External Links
| Links for MAFG-AS1 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |